Table 2 Distribution of KRAS and BRAF mutations in colorectal cancer patients, number and (percentage)
From: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
Gene | Nucleotide | Protein effect | Primary tumors | Metastasis | Both |
|---|---|---|---|---|---|
KRAS | c.34G>A | p.G12S | 19 (4.9%) | 19 (4.2%) | |
c.34G>C | p.G12R | 9 (2.3%) | 1 (1.6%) | 10 (2.2%) | |
c.34G>T | p.G12C | 33 (8.5%) | 6 (9.8%) | 39 (8.7%) | |
c.35G>A | p.G12D | 146 (37.5%) | 13 (21.3%) | 159 (35.3%) | |
c.35G>C | p.G12A | 22 (5.7%) | 4 (6.6%) | 26 (5.8%) | |
c.35G>T | p.G12V | 73 (18.7%) | 18 (29.5%) | 91 (20.2%) | |
c.37G>T | p.G13C | 3 (0.8%) | 3 (0.7%) | ||
c.38G>A | p.G13D | 81 (20.8%) | 18 (29.5%) | 99 (22.0%) | |
c.34G>C/34G>T | Unknown | 1 (1.6%) | 1 (0.2%) | ||
c.34G>T/35G>T | Unknown | 2 (0.5%) | 2 (0.4%) | ||
c.38G>T/39C>T | Unknown | 1 (0.3%) | 1 (0.2%) | ||
BRAF | c.1799T>A | p.V600E | 26 (6.5%) |
